Recruiting

Exercise & Liraglutide

Sponsor:

University of Virginia

Code:

NCT03883412

Conditions

Type2 Diabetes

Eligibility Criteria

Sex: All

Age: 21 - 60

Healthy Volunteers: Accepted

Interventions

Exercise

Liraglutide

Study Details

Brief summary:

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Conditions

Type2 Diabetes

Study ID

NCT03883412

Start date

Feb 28, 2019

Status verified date

Aug, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 21-60
  • A1C ≤ 8.5%
  • Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
  • On stable dose of oral hypoglycemic agents >4 months
  • On stable dose of other medications for >4 months

Exclusion Criteria:

  • Taking Insulin
  • Smoking presently or in the past 6 months
  • BP >160/90
  • BMI >35
  • Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
  • History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
  • Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
  • Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
  • Pregnant or breastfeeding.
  • Known hypersensitivity to perflutren (contained in Definity)

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Factorial

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Exercise Alone

16 weeks of treatment

experimental: Liraglutide alone

16 weeks of treatment

experimental: Exercise + Liraglutide

16 weeks of treatment

Interventions

Exercise

16 weeks of treatment

Liraglutide

16 weeks of Liraglutide

Primary outcome measure

  • Microvascular Blood Volume - change from baseline [ Time Frame: 16 weeks ]

Central Contacts and Locations

Central contacts

Lee Hartline, MEd

434-924-5247lmh9d@virginia.eud

Linda Jahn, RN, MEd

434-924-1134las6e@virginia.edu

Locations

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22906

Contacts

Zhenqi Liu, MD

434-243-2603zl3e@virginia.edu

Eugene Barrett, MD, PhD

434-924-1175ejb8x@virginia.edu

More Information

Sponsor

University of Virginia

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Virginia on 2026-08-12.